Harvard Breast Cancer New Horizons, Current Controversies 2025

Description Include:  videos   pdf, size:  GB Target Audience: surgical, and radiation oncologists, breast surgeons Sample video: contact me for sample video Information: Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of health care professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients. The two-day course is taught by clinical experts in medical oncology, surgical oncology, radiation oncology, and pathology. Each year, the course faculty identify emerging practice gaps in breast oncology and address those gaps by translating the latest scientific knowledge into practical clinical applications. Course participants engage with the material through interactive learning formats, including group case discussions, question and answer sessions, and panel presentations. This interactive learning process assists healthcare professionals in integrating the latest evidence-based information on breast cancer screening, diagnosis, treatment, and long-term monitoring into their clinical practices. This year, we will be again offering an in-person program as well as a livestream for those who still do not feel comfortable traveling to Boston. Continuing with the livestream allows participants to engage with our faculty from the convenience of their own community, be it in Boston or across the globe. This hybrid format worked very well last year and is appropriate given both the range of potential attendees and persistent uncertainty over travel and large group gatherings. The timing of the course for summer 2025 is particularly fortuitous owing to the extraordinary progress happening in breast cancer. In the last two years, we have seen transformative breakthroughs in all types of breast cancer treatment: FDA approval of novel antibody-drug conjugates for the treatment of advanced hormone receptor-positive, HER2-positive, and triple-negative breast cancer, with new data showing benefit of these agents in tumor types beyond their initial application. FDA approval of the first-in-class oral SERD elacestrant in hormone receptor-positive metastatic breast cancer, with companion diagnostic genomic testing for targetable ESR1 mutations. FDA approval of the AKT pathway inhibitor capivasertib in combination with fulvestrant for patients with hormone receptor-positive, PIK3CA/AKT/PTEN-mutant metastatic breast cancer and reported phase III data of another agent in this class (inavolisib). FDA approval of the CDK4/6 inhibitor abemaciclib in high-risk, early-stage hormone receptor-positive breast cancer, and mature data showing compelling benefits including overall survival for this class of drugs in advanced breast cancer, as well as preliminary reports of a second agent in this class (ribociclib) with adjuvant efficacy. FDA approval of a novel antibody-drug conjugate for patients with a HER2-low metastatic breast cancer. Learning Objectives Apply knowledge of recent clinical data together with current expert recommendations to patient selection for new and emerging therapies for advanced breast cancer. Select appropriate risk assessment modalities, where applicable, and make evidence-based therapeutic selections for women who are candidates for neoadjuvant or adjuvant therapy and know the limitations of genomic testing. Apply recent clinical data and expert recommendations to the management of women with breast cancer who are treated with mastectomy, including integration of surgical methods, breast reconstruction options, and post-mastectomy radiation if needed. Assess current practices regarding symptom management during active treatment and in survivorship and consider the needs for fertility and lifestyle counseling among patients with breast cancer and survivors and improve current practices if needed. Evaluate the genetic and personal risk factors of breast cancer and utilize appropriate genetic testing for hereditary breast cancer. Participant Types Nurse Practitioners, Primary Care Physicians, Physician Assistants, Nurses, Pharmacists, and Specialty Physicians   Topics: Day 1 – Thursday, July 17, 2025 Theme: Advances in Radiation Therapy, Pathology, and Breast Cancer Management Welcoming Remarks Speaker: Harold BursteinTime: 8:00 – 8:15 am Session I: Radiation Oncology Time Session Title Speaker(s) 8:15 – 8:35 am 50 Years of Radiation Therapy Abram Recht 8:35 – 8:55 am Standard Radiation Therapy: The Long and the Short Julia Wong 8:55 – 9:15 am The Future of Breast Radiation Therapy Atif Khan 9:15 – 9:35 am Radiopharmaceuticals Heather Jacene 9:35 – 9:50 am Q&A Abram Recht, Atif Khan, Julia Wong, Heather Jacene Session II: Pathology Time Session Title Speaker(s) 9:50 – 10:10 am Lobular Breast Cancer Stuart Schnitt 10:10 – 10:30 am ctDNA: The Evolving Role for Molecular Diagnostics Stefania Morganti 10:30 – 10:45 am Q&A Stuart Schnitt, Stefania Morganti Special Lecture Time: 11:00 – 11:40 amSpeaker(s): Sydney Smith & Julie BosworthTopic: What’s New in Supportive Care: Management of Gastrointestinal Side Effects Time Session Title Speaker(s) 11:00 – 11:20 am Essentials of Germline Genetics Judy Garber 11:20 – 11:40 am Q&A Julie Bosworth, Sydney Smith, Judy Garber Schwartz Rounds: A Complex Case Speaker: Ann PartridgeTime: 11:50 am – 12:20 pmQ&A: 12:20 – 12:30 pm Tumor Board: Early Breast Cancer Time Speaker(s) 12:40 – 1:40 pm Harold Burstein, Faina Nakhlis, Julia Wong, Brittany Bychkovsky, Adrienne Waks, Filipa Lynce, Elizabeth Mittendorf Session III: HER2 Positive Breast Cancer Time Session Title Speaker(s) 1:50 – 2:10 pm New Approaches in Early Stage HER2 Positive Breast Cancer Adrienne Waks 2:10 – 2:30 pm The Progress Continues: Late Stage HER2 Positive Breast Cancer Sarah Sammons 2:30 – 2:50 pm Can We Cure Metastatic Breast Cancer? Nancy Lin 2:50 – 3:05 pm Q&A Sara Tolaney, Sarah Sammons, Nancy Lin, Adrienne Waks Special Lecture Time: 3:20 – 4:35 pmSpeaker(s): Erica Warner, Filipa Lynce, Antonio Giordano, Jennifer Ligibel Time Session Title Speaker(s) 3:20 – 3:45 pm Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype Erica Warner 3:45 – 4:10 pm Inflammatory Breast Cancer Filipa Lynce 4:10 – 4:35 pm Early Drug Discovery in Breast Cancer Antonio Giordano 4:35 – 5:00 pm Lifestyle/Diet/Exercise in Breast Cancer Patients Jennifer Ligibel Reception Time: 5:00 – 6:00 pm Day 2 – Friday, July 18, 2025 Theme: Surgical Interventions and Advanced Breast Cancer Treatment Session IV: Surgery Time Session Title Speaker(s) 8:00 – 8:20 am Oncoplastic Reconstruction: Common Indications and Outcomes Indranil Sinha 8:20 – 8:40 am The Axilla After Neoadjuvant Therapy: How Much Is Too Much? Elizabeth Mittendorf 8:40 – 9:00 am Implications of the SOUND Trial Olga Kantor 9:00 – 9:20 am Cryoblation Instead of Surgery Francys Verdial 9:20 – 9:35 am Q&A Barbara Smith, Indranil Sinha, Olga Kantor, Francys Verdial, Elizabeth Mittendorf Schlager Lecture: Immunotherapy in Early Breast Cancer: Today and Tomorrow Speaker: Marleen KokTime: 9:35 – 10:20 am Session V: Triple Negative Breast Cancer (TNBC) Time Session Title Speaker(s) 10:35 – 10:55 am Small TNBCs: How Small Is Small Enough? Steven Isakoff 10:55 – 11:15 am Antibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer Ana Garrido-Castro 11:15 – 11:35 am Immunotherapy in TNBC Guilherme Nader Marta 11:35 – 11:55 am Managing Endocrine Side Effects of Immunotherapy Elad Sharon 11:55 am – 12:10 pm Q&A Steven Isakoff, Ana Garrido-Castro, Guilherme Nader Marta, Elad Sharon Tumor Board: Advanced Breast Cancer Time Speaker(s) 12:20 – 1:30 pm Rachel Freedman, Barbara Smith, Sarah Sammons, Erica Mayer, Laura Spring, Leticia Varella, Guilherme Nader Marta, Daniel Abravanel Session VI: ER Positive Breast Cancer Time Session Title Speaker(s) 1:40 – 2:00 pm New Approaches in Early ER Positive Breast Cancer Erica Mayer 2:00 – 2:20 pm PI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target Dejan Juric 2:20 – 2:40 pm Advanced ER Positive Breast Cancer: A Surfeit of Choices Seth Wander 2:40 – 3:00 pm Emerging Antibody Drug Conjugates in ER Positive Breast Cancer Paolo Tarantino 3:00 – 3:15 pm Q&A Erica Mayer, Seth Wander, Paolo Tarantino, Dejan Juric CDK4/6: Which One? For Whom? – Debate Speakers: Shana Berwick, Laura SpringTime: 3:15 – 3:30 pm ASCO Highlights Speaker: Harold BursteinTime: 3:30 – 4:25 pm Closing Remarks Speaker: Harold BursteinTime: 4:25 – 4:45 pm